{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T11:53:18Z","timestamp":1742385198571},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T00:00:00Z","timestamp":1686700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T00:00:00Z","timestamp":1686700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s00108-023-01523-z","type":"journal-article","created":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T16:01:50Z","timestamp":1686758510000},"page":"701-707","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapie der Tuberkulose: Was gibt es Neues?","Treatment of tuberculosis: what is new?"],"prefix":"10.1007","volume":"64","author":[{"given":"Thomas Theo","family":"Brehm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niklas","family":"K\u00f6hler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Schmiedel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Terhalle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Martensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Kalsdorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janne","family":"Kandulla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Heyckendorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Kuhns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inna","family":"Friesen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Lange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,14]]},"reference":[{"key":"1523_CR1","volume-title":"Global tuberculosis report 2022","author":"World Health Organization","year":"2022","unstructured":"World Health Organization (2022) Global tuberculosis report 2022. World Health Organization, Geneva"},{"key":"1523_CR2","volume-title":"Bericht zur Epidemiologie der Tuberkulose in Deutschland f\u00fcr 2021","author":"Robert Koch-Institut","year":"2022","unstructured":"Robert Koch-Institut (2022) Bericht zur Epidemiologie der Tuberkulose in Deutschland f\u00fcr 2021. Robert Koch-Institut, Berlin"},{"key":"1523_CR3","unstructured":"https:\/\/www.who.int\/news\/item\/27-01-2021-who-announces-updated-definitions-of-extensively-drug-resistant-tuberculosis. Zugegriffen: 16. Mai 2023"},{"key":"1523_CR4","volume-title":"Tuberculosis surveillance and monitoring in Europe 2022","author":"European Centre for Disease Prevention and Control. & World Health Organization. Regional Office for Europe","year":"2020","unstructured":"European Centre for Disease Prevention and Control. & World Health Organization. Regional Office for Europe (2020) Tuberculosis surveillance and monitoring in Europe 2022"},{"issue":"5","key":"1523_CR5","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1183\/09031936.00120908","volume":"33","author":"U Mack","year":"2009","unstructured":"Mack\u00a0U, Migliori\u00a0GB, Sester\u00a0M, Rieder\u00a0HL, Ehlers\u00a0S, Goletti\u00a0D et\u00a0al (2009) LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir\u00a0J 33(5):956\u2013973","journal-title":"Eur Respir J"},{"issue":"11","key":"1523_CR6","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1055\/a-1934-8303","volume":"76","author":"T Schaberg","year":"2022","unstructured":"Schaberg\u00a0T, Brinkmann\u00a0F, Feiterna-Sperling\u00a0C, Geerdes-Fenge\u00a0H, Hartmann\u00a0P, H\u00e4cker\u00a0B et al (2022) Tuberculosis in adulthood\u2014The Sk2-Guideline of the German Central Committee against Tuberculosis (DZK) and the German Respiratory Society (DGP) for the diagnosis and treatment of adult tuberculosis patients. Pneumologie 76(11):727\u2013819","journal-title":"Pneumologie"},{"issue":"10","key":"1523_CR7","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1055\/s-0043-116545","volume":"71","author":"C Feiterna-Sperling","year":"2017","unstructured":"Feiterna-Sperling\u00a0C, Brinkmann\u00a0F, Adamczick\u00a0C, Ahrens\u00a0F, Barker\u00a0M, Berger\u00a0C et al (2017) Consensus-Based Guidelines for Diagnosis, Prevention and Treatment of Tuberculosis in Children and Adolescents\u2014A Guideline on Behalf of the German Society for Pediatric Infectious Diseases (DGPI). Pneumologie 71(10):629\u2013680","journal-title":"Pneumologie"},{"issue":"12","key":"1523_CR8","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1038\/s41591-020-1076-0","volume":"26","author":"RK Gupta","year":"2020","unstructured":"Gupta\u00a0RK, Calderwood\u00a0CJ, Yavlinsky\u00a0A, Krutikov\u00a0M, Quartagno\u00a0M, Aichelburg\u00a0MC et\u00a0al (2020) Discovery and validation of a\u00a0personalized risk predictor for incident tuberculosis in low transmission settings. Nat Med 26(12):1941\u20131949","journal-title":"Nat Med"},{"issue":"18","key":"1523_CR9","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1056\/NEJMoa2033400","volume":"384","author":"SE Dorman","year":"2021","unstructured":"Dorman\u00a0SE, Nahid\u00a0P, Kurbatova\u00a0EV, Phillips\u00a0PPJ, Bryant\u00a0K, Dooley\u00a0KE et al (2021) Four-month Rifapentine regimens with or without Moxifloxacin for tuberculosis. N\u00a0Engl J Med 384(18):1705\u20131718","journal-title":"N Engl J Med"},{"key":"1523_CR10","volume-title":"Treatment of drug-susceptible tuberculosis: rapid communication","author":"World Health Organization","year":"2021","unstructured":"World Health Organization (2021) Treatment of drug-susceptible tuberculosis: rapid communication. World Health Organization, Geneva"},{"key":"1523_CR11","unstructured":"Treatment Action Group (2020) An activist\u2019s guide to rifapentine for the treatment of TB infection. https:\/\/www.treatmentactiongroup.org\/publication\/an-activists-guide-to-rifapentine-for-the-treatment-of-tb-infection\/. Zugegriffen: 16. Mai 2023"},{"key":"1523_CR12","doi-asserted-by":"publisher","unstructured":"Paton NI, Cousins C, Suresh C, Burhan E, Chew KL, Dalay VB et al (2023) Treatment strategy for Rifampin-susceptible tuberculosis. N Engl J Med 388(10):873\u2013887. https:\/\/doi.org\/10.1056\/NEJMoa2212537","DOI":"10.1056\/NEJMoa2212537"},{"key":"1523_CR13","volume-title":"Global tuberculosis report 2022","author":"World Health Organization","year":"2022","unstructured":"World Health Organization (2022) Global tuberculosis report 2022. WHO, Geneva"},{"issue":"10","key":"1523_CR14","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1056\/NEJMoa1901814","volume":"382","author":"F Conradie","year":"2020","unstructured":"Conradie\u00a0F, Diacon\u00a0AH, Ngubane\u00a0N, Howell\u00a0P, Everitt\u00a0D, Crook\u00a0AM et al (2020) Treatment of highly drug-resistant pulmonary tuberculosis. N\u00a0Engl J Med 382(10):893\u2013902","journal-title":"N Engl J Med"},{"issue":"9","key":"1523_CR15","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa2119430","volume":"387","author":"F Conradie","year":"2022","unstructured":"Conradie\u00a0F, Bagdasaryan\u00a0TR, Borisov\u00a0S, Howell\u00a0P, Mikiashvili\u00a0L, Ngubane\u00a0N et al (2022) Bedaquiline-pretomanid-Linezolid regimens for drug-resistant tuberculosis. N\u00a0Engl J Med 387(9):810\u2013823","journal-title":"N Engl J Med"},{"issue":"25","key":"1523_CR16","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1056\/NEJMoa2117166","volume":"387","author":"BT Nyang\u2019wa","year":"2022","unstructured":"Nyang\u2019wa\u00a0BT, Berry\u00a0C, Kazounis\u00a0E, Motta\u00a0I, Parpieva\u00a0N, Tigay\u00a0Z et al (2022) A 24-week, all-oral regimen for rifampin-resistant tuberculosis. N\u00a0Engl J Med 387(25):2331\u20132343","journal-title":"N Engl J Med"},{"issue":"10366","key":"1523_CR17","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1016\/S0140-6736(22)02078-5","volume":"400","author":"RL Goodall","year":"2022","unstructured":"Goodall\u00a0RL, Meredith\u00a0SK, Nunn\u00a0AJ, Bayissa\u00a0A, Bhatnagar\u00a0AK, Bronson\u00a0G et al (2022) Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial. Lancet 400(10366):1858\u20131868","journal-title":"Lancet"},{"key":"1523_CR18","series-title":"Contract No.: Licence: CC BY-NC-SA 3.0 IGO","volume-title":"WHO operational handbook on tuberculosis. Module 4: treatment\u2014drug-resistant tuberculosis treatment, update","author":"World Health Organization","year":"2022","unstructured":"World Health Organization (2022) WHO operational handbook on tuberculosis. Module 4: treatment\u2014drug-resistant tuberculosis treatment, update. Contract No.: Licence: CC BY-NC-SA 3.0 IGO. WHO, Geneva"},{"issue":"8","key":"1523_CR19","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1164\/rccm.201606-1097LE","volume":"194","author":"C Lange","year":"2016","unstructured":"Lange\u00a0C, Duarte\u00a0R, Frechet-Jachym\u00a0M, Guenther\u00a0G, Guglielmetti\u00a0L, Olaru\u00a0ID et al (2016) Limited benefit of the new shorter multidrug-resistant tuberculosis regimen in europe. Am J Respir Crit Care Med 194(8):1029\u20131031","journal-title":"Am J Respir Crit Care Med"},{"issue":"10150","key":"1523_CR20","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/S0140-6736(18)31644-1","volume":"392","author":"N Ahmad","year":"2018","unstructured":"Collaborative Group for the Meta-Analysis of Individual Patient Data in MDRTBt, Ahmad\u00a0N, Ahuja\u00a0SD, Akkerman\u00a0OW, Alffenaar\u00a0JC, Anderson\u00a0LF et al (2018) Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet 392(10150):821\u2013834","journal-title":"Lancet"},{"issue":"2","key":"1523_CR21","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1159\/000528274","volume":"102","author":"JM Aguilar Diaz","year":"2023","unstructured":"Aguilar Diaz\u00a0JM, Abulfathi\u00a0AA, Te Brake\u00a0LH, van Ingen\u00a0J, Kuipers\u00a0S, Magis-Escurra\u00a0C et al (2023) New and repurposed drugs for the treatment of active tuberculosis: an update for clinicians. Respiration 102(2):83\u2013100","journal-title":"Respiration"},{"key":"1523_CR22","volume-title":"WHO consolidated guidelines on tuberculosis. Module 4: treatment\u2014drug-resistant tuberculosis treatment (update)","author":"World Health Organization","year":"2022","unstructured":"World Health Organization (2022) WHO consolidated guidelines on tuberculosis. Module 4: treatment\u2014drug-resistant tuberculosis treatment (update). Geneva, Switzerland"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-023-01523-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-023-01523-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-023-01523-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T09:04:14Z","timestamp":1687338254000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-023-01523-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,14]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["1523"],"URL":"https:\/\/doi.org\/10.1007\/s00108-023-01523-z","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,14]]},"assertion":[{"value":"20 April 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"C.\u00a0Lange gibt an Honorare f\u00fcr Vortr\u00e4ge auf Symposien erhalten zu haben, die von den Firmen Insmed und Gilead finanziell unterst\u00fctzt wurden. Er hat Honorare f\u00fcr wissenschaftliche Beratungen der Fa. Insmed erhalten. Er ist wissenschaftlicher Berater von \u00c4rzte ohne Grenzen (MSF) f\u00fcr Arzneimittelstudien der Tuberkulose. B.\u00a0Kalsdorf hat Honorare f\u00fcr Vortr\u00e4ge von der Fa. Insmed erhalten. T.T.\u00a0Brehm, N.\u00a0K\u00f6hler, S.\u00a0Schmiedel, E.\u00a0Terhalle, J.\u00a0Martensen, J.\u00a0Kandulla, J.\u00a0Heyckendorf, M.\u00a0Kuhns und I.\u00a0Friesen geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}